BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.

Autor: Guerrero P; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Albarrán V; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., San Román M; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., González-Merino C; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., García de Quevedo C; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Moreno J; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Calvo JC; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., González G; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Orejana I; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Chamorro J; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Martínez-Delfrade Í; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Morón B; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., de Frutos B; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Ferreiro MR; Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Oct 31; Vol. 15 (21). Date of Electronic Publication: 2023 Oct 31.
DOI: 10.3390/cancers15215243
Abstrakt: Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje